IMAGiNe study: IgM (anti-MAG) peripheral Neuropathy
Research type
Research Study
Full title
IgM (anti-MAG) peripheral Neuropathy: From proper Assessment to Trial needs – IMAGiNe study
IRAS ID
334136
Contact name
Stephen Keddie
Contact email
Sponsor organisation
Barts Health NHS trust
Clinicaltrials.gov Identifier
N/A, N/A
Duration of Study in the UK
10 years, 0 months, 1 days
Research summary
IgM paraproteinaemic neuropathy is a type of nerve damage (neuropathy) caused by the presence of an abnormal antibody called an IgM paraprotein, which can target and damage the myelin sheath surrounding nerves, leading to symptoms like numbness, tingling, weakness, and sometimes tremor, usually affecting the hands and feet first; it's often associated with a condition called monoclonal gammopathy of undetermined significance (MGUS) and can be diagnosed by blood tests detecting the specific IgM antibody involved. It is a rare disease that can progress differently in different patients.
This study investigates which factors influence and predict the course of IgM paraprotein associated polyneuropathy. The study also aims to develop new tests and questionnaires to record the severity of symptoms. There are at least 500 patients from various international hospitals that will participate in this study. Historical data such as clinical data on neurological function and results from blood tests and nerve conduction tests will be collected. Patients will also be invited to visit the hospital several times for a neurological examination and to fill in questionnaires at home. This study should provide clinicians with enhanced knowledge of this rare condition and it's clinical presentation, investigation results and natural history. It should additionally enable clinicians to estimate which patients will respond to treatment.
REC name
South West - Frenchay Research Ethics Committee
REC reference
26/SW/0017
Date of REC Opinion
23 Feb 2026
REC opinion
Favourable Opinion